1. Home
  2. STTK vs ETO Comparison

STTK vs ETO Comparison

Compare STTK & ETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.36

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Tax-Advantage Global Dividend Opp

ETO

Eaton Vance Tax-Advantage Global Dividend Opp

HOLD

Current Price

$30.19

Market Cap

493.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
ETO
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
538.3M
493.0M
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
STTK
ETO
Price
$7.36
$30.19
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
1.9M
24.8K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$25.68
52 Week High
$8.33
$31.26

Technical Indicators

Market Signals
Indicator
STTK
ETO
Relative Strength Index (RSI) 58.96 43.15
Support Level $5.87 $29.52
Resistance Level $7.64 $30.83
Average True Range (ATR) 0.62 0.37
MACD 0.00 -0.08
Stochastic Oscillator 71.63 15.56

Price Performance

Historical Comparison
STTK
ETO

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About ETO Eaton Vance Tax-Advantage Global Dividend Opp

Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas, and consumable fuels, personal products, and other areas.

Share on Social Networks: